Abstract: The invention provides a composition comprising SGEF protein or gene as a therapeutic means to clinical or subclinical defects associated with anomalies of at least one from among the macula, corpus callosum, hippocampus, liver or immune system and diseases including a feverless response to infection, a cancer or vision loss. Methods of diagnosis of such disease and development anomalies are based on detection of mutations of the SGEF gene or altered levels of the SGEF mRNA or protein. A change of at least about 20% in the level of expression visa-vie a normal individual indicates an SGEF anomaly. The SGEF protein is also used as a preventive or curative treatment of atherosclerosis by local or systemic delivery. The invention also provides a composition comprising an inhibitor of the SGEF gene expression or SGEF protein concentration, as a therapeutic means for glaucoma, osteoarthritis, auto-inflammatory diseases, tumors or cancers.

Abstract: Described is a system, method and apparatus for measuring a vibrational response in an eye for determination of ocular parameters such as intraocular pressure, corneal elasticity and scleral pressure. The method comprises positioning an air jet nozzle to direct an excitation stimulus at a single frequency to the apex of the eye along the optical axis of the eye; positioning a sensor to direct incident light at a fixed position of the eye distinct from the apex of the eye; exciting vibration in the eye with the excitation stimulus; directing incident light from the sensor to the fixed position of the eye; and detecting backscatter light from the eye with the sensor, to measure the vibrational response. Algorithms are used to calculate the ocular pressure from the vibrational response of the cornea or sclera. The method does not require contact with the eye, and is reliable and accurate.

Abstract: Described is a system, method and apparatus for measuring a vibrational response in an eye for determination of ocular parameters such as intraocular pressure, corneal elasticity and scleral pressure. The method comprises positioning an air jet nozzle to direct an excitation stimulus at a single frequency to the apex of the eye along the optical axis of the eye; positioning a sensor to direct incident light at a fixed position of the eye distinct from the apex of the eye; exciting vibration in the eye with the excitation stimulus; directing incident light from the sensor to the fixed position of the eye; and detecting backscatter light from the eye with the sensor, to measure the vibrational response. Algorithms are used to calculate the ocular pressure from the vibrational response of the cornea or sclera. The method does not require contact with the eye, and is reliable and accurate.

Abstract: Microspheres, typically sterile, inert, silica glass microspheres, are dispersed in a carrier suitable for use relative to the object to be imaged and analyzed. In the case of ophthalmic imaging, an ophthalmically-acceptable gel is used and the resulting composition is dispensed into a mammalian eye. The gel and microspheres dispersed therein coat and conform to the surface of the eye. The microspheres enhance reflectance from the eye which improves signal-to-noise ratio and improves imaging quality.

Abstract: Microspheres, typically sterile, inert, silica glass microspheres, are dispersed in a carrier suitable for use relative to the object to be imaged and analyzed. In the case of ophthalmic imaging, an ophthalmically-acceptable gel is used and the resulting composition is dispensed into a mammalian eye. The gel and microspheres dispersed therein coat and conform to the surface of the eye. The microspheres enhance reflectance from the eye which improves signal-to-noise ratio and improves imaging quality.

Abstract: The invention provides a composition comprising SGEF protein or gene as a therapeutic means to clinical or subclinical defects associated with anomalies of at least one from among the macula, corpus callosum, hippocampus, liver or immune system and diseases including a feverless response to infection, a cancer or vision loss. Methods of diagnosis of such disease and development anomalies are based on detection of mutations of the SGEF gene or altered levels of the SGEF mRNA or protein. A change of at least about 20% in the level of expression visa-vie a normal individual indicates an SGEF anomaly. The SGEF protein is also used as a preventive or curative treatment of atherosclerosis by local or systemic delivery. The invention also provides a composition comprising an inhibitor of the SGEF gene expression or SGEF protein concentration, as a therapeutic means for glaucoma, osteoarthritis, auto-inflammatory diseases, tumors or cancers.

Abstract: The invention provides a composition comprising SGEF protein or gene as a therapeutic means to clinical or subclinical defects associated with anomalies of at least one from among the macula, corpus callosum, hippocampus, liver or immune system or feverless response to infection. Methods of diagnosis of such disease and development anomalies are based on detection of mutations of the SGEF gene. The SGEF protein is also used as a preventive or curative treatment of atherosclerosis by local or systemic delivery. The invention also provides a composition comprising an inhibitor of the SGEF gene expression or SGEF protein concentration, as a therapeutic means for glaucoma, osteoarthritis, auto-inflammatory diseases, tumors or cancers.